These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25711323)

  • 1. Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Soliman EZ; Sharma S; Arastéh K; Wohl D; Achhra A; Tambussi G; O'Connor J; Stein JH; Duprez DA; Neaton JD; Phillips A;
    HIV Med; 2015 Apr; 16 Suppl 1(0 0):46-54. PubMed ID: 25711323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Kunisaki KM; Niewoehner DE; Collins G; Nixon DE; Tedaldi E; Akolo C; Kityo C; Klinker H; La Rosa A; Connett JE;
    HIV Med; 2015 Apr; 16 Suppl 1(0 0):119-28. PubMed ID: 25711330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Achhra AC; Mocroft A; Ross MJ; Ryom L; Lucas GM; Furrer H; Neuhaus J; Somboonwit C; Kelly M; Gatell JM; Wyatt CM;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):55-63. PubMed ID: 25711324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease.
    Guo F; Hsieh E; Lv W; Han Y; Xie J; Li Y; Song X; Li T
    BMC Infect Dis; 2017 Apr; 17(1):287. PubMed ID: 28427339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Baker JV; Engen NW; Huppler Hullsiek K; Stephan C; Jain MK; Munderi P; Pett S; Duprez D;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):109-18. PubMed ID: 25711329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Carr A; Grund B; Neuhaus J; Schwartz A; Bernardino JI; White D; Badel-Faesen S; Avihingsanon A; Ensrud K; Hoy J;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):137-46. PubMed ID: 25711332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Wright EJ; Grund B; Cysique LA; Robertson KR; Brew BJ; Collins G; Shlay JC; Winston A; Read TR; Price RW;
    HIV Med; 2015 Apr; 16 Suppl 1():97-108. PubMed ID: 25711328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.
    Friis-Møller N; Ryom L; Smith C; Weber R; Reiss P; Dabis F; De Wit S; Monforte AD; Kirk O; Fontas E; Sabin C; Phillips A; Lundgren J; Law M;
    Eur J Prev Cardiol; 2016 Jan; 23(2):214-23. PubMed ID: 25882821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of hypertension and cardiovascular risk factors among long-term AIDS survivors: A report from the field.
    Pierre S; Seo G; Rivera VR; Walsh KF; Victor JJ; Charles B; Julmiste G; Dumont E; Apollon A; Cadet M; Saint-Vil A; Marcelin A; Severe P; Lee MH; Kingery J; Koenig S; Fitzgerald D; Pape J; McNairy ML
    J Clin Hypertens (Greenwich); 2019 Oct; 21(10):1558-1566. PubMed ID: 31448551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated risk of cardiovascular disease among the HIV-positive patients aged 40 years or older in Taiwan.
    Wu PY; Chen MY; Sheng WH; Hsieh SM; Chuang YC; Cheng A; Pan SC; Wu UI; Chang HY; Luo YZ; Yang SP; Zhang JY; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2019 Aug; 52(4):549-555. PubMed ID: 31036484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models.
    Krikke M; Hoogeveen RC; Hoepelman AI; Visseren FL; Arends JE
    HIV Med; 2016 Apr; 17(4):289-97. PubMed ID: 26268806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Lifson AR; Grandits GA; Gardner EM; Wolff MJ; Pulik P; Williams I; Burman WJ;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):88-96. PubMed ID: 25711327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Matthews GV; Neuhaus J; Bhagani S; Mehta SH; Vlahakis E; Doroana M; Naggie S; Arenas-Pinto A; Peters L; Rockstroh JK;
    HIV Med; 2015 Apr; 16 Suppl 1():129-36. PubMed ID: 25711331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.
    Lichtenstein KA; Armon C; Buchacz K; Chmiel JS; Buckner K; Tedaldi EM; Wood K; Holmberg SD; Brooks JT;
    Clin Infect Dis; 2010 Aug; 51(4):435-47. PubMed ID: 20597691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk factors among Ghanaian patients with HIV: A cross-sectional study.
    Appiah LT; Sarfo FS; Huffman MD; Nguah SB; Stiles JK
    Clin Cardiol; 2019 Dec; 42(12):1195-1201. PubMed ID: 31571256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain.
    Estrada V; Bernardino JI; Masiá M; Iribarren JA; Ortega A; Lozano F; Miralles C; Olalla J; Santos J; Elías MJ; Domingo P; Cruz AF
    HIV Clin Trials; 2015; 16(2):57-65. PubMed ID: 25874992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV.
    van Zoest RA; Law M; Sabin CA; Vaartjes I; van der Valk M; Arends JE; Reiss P; Wit FW
    J Acquir Immune Defic Syndr; 2019 Aug; 81(5):562-571. PubMed ID: 31045648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Law MG; Achhra A; Deeks SG; Gazzard B; Migueles SA; Novak RM; Ristola M;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):37-45. PubMed ID: 25711322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Baxter JD; Dunn D; White E; Sharma S; Geretti AM; Kozal MJ; Johnson MA; Jacoby S; Llibre JM; Lundgren J;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):77-87. PubMed ID: 25711326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and correlates of traditional risk factors for cardiovascular disease in a Nigerian ART-naive HIV population: a cross-sectional study.
    Ekrikpo UE; Akpan EE; Ekott JU; Bello AK; Okpechi IG; Kengne AP
    BMJ Open; 2018 Jul; 8(7):e019664. PubMed ID: 30030310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.